Using indocyanine green and methylene blue for axillary reverse mapping in modified radical mastectomy for breast cancer

---

Review Article

Author Details : Rabinarayan Guru*, Jhilik Ghosh, Atul Chauhan, Win Verlina Routray

Volume : 9, Issue : 2, Year : 2024

Article Page : 95-99

https://doi.org/10.18231/j.jdpo.2024.018

Suggest article by email

Get Permission

---

Abstract

Introduction: Axillary Reverse Mapping (ARM) is a method used to identify the lymph nodes (known as ARM nodes) and lymphatic vessels of the upper limb that pass through the axillary region during breast cancer surgery. It is also known as DUAL mapping or SPLIT mapping. The main goal of ARM is to decrease the occurrence of arm lymphedema. This is based on the hypothesis that the ARM procedure reveals an alternative lymphatic pathway originating from the arm.
To assess the rates of intraoperative identification and metastasis of ARM nodes.
Results: The ARM node identification rate was 83.33%. In our study, the visualization rate in the methylene blue plus ICG group was significantly higher at 95.8% (23 out of 24) compared to 75% (18 out of 24) in the methylene blue alone group.
Conclusion: Using methylene blue combined with ICG for ARM achieves a higher identification rate of ARM nodes compared to methylene blue alone, making it a promising technique for surgical treatment in patients with invasive breast cancer.
 

Keywords: MRM­Modified Radical Mastectomy, ARM­Axillary Reverse Mapping, ICG­Indocyanine Green, MB­Methylene Blue, ALND­Axillary Lymph Node Dissection, SLNB: Sentinel Lymph Node Biopsy

How to cite : Guru R, Ghosh J, Chauhan A, Routray W V, Using indocyanine green and methylene blue for axillary reverse mapping in modified radical mastectomy for breast cancer. IP J Diagn Pathol Oncol 2024;9(2):95-99

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.